Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Up 2,767.7% in June

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 493,245 shares, a growth of 2,767.7% from the May 31st total of 17,200 shares. Based on an average trading volume of 5,161,875 shares, the short-interest ratio is currently 0.1 days. Approximately 0.6% of the company’s shares are short sold.

Hedge Funds Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 7.06% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Indaptus Therapeutics Stock Down 8.2%

NASDAQ:INDP traded down $0.29 during trading hours on Thursday, reaching $3.26. 92,782 shares of the stock were exchanged, compared to its average volume of 2,953,706. Indaptus Therapeutics has a twelve month low of $0.92 and a twelve month high of $13.44. The business has a 50-day moving average of $2.62 and a two-hundred day moving average of $2.34. The company has a market capitalization of $369.16 million, a price-to-earnings ratio of -0.21 and a beta of 1.25.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.87) by $1.64.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.